Proportion of patients with residual disease at Week 24 across each remission definition.
| Variables | VLDA Remission | DAPSA Remission | cDAPSA Remission | DAPSA Remission+ VLDA Remission−* |
|---|---|---|---|---|
| Dactylitis (1–3) | 2/68 (2.9) | 5/231 (2.2) | 5/250 (2.0) | 3/166 (1.8) |
| Enthesitis (3) | 0/68 (0.0) | 1/232 (0.4) | 1/251 (0.4) | 1/167 (0.6) |
| HAQ score > 0.5 | 0/68 (0.0) | 15/231 (6.5) | 17/250 (6.8) | 15/166 (9.0) |
| PASI score 0 | 47/68 (69.1) | 54/232 (23.3) | 58/251 (23.1) | 8/167 (4.8) |
| PASI score 1 | 21/68 (30.9) | 50/232 (21.6) | 53/251 (21.1) | 31/167 (18.6) |
| PASI score 2–9 | 0/68 (0.0) | 114/232 (49.1) | 123/251 (49.0) | 114/167 (68.3) |
| PASI score ≥ 10 | 0/68 (0.0) | 14/232 (6.0) | 17/251 (6.8) | 14/167 (8.4) |
| SJC > 1 | 0/68 (0.0) | 7/232 (3.0) | 9/251 (3.6) | 7/167 (4.2) |
| TJC > 1 | 0/68 (0.0) | 7/232 (3.0) | 9/251 (3.6) | 7/167 (4.2) |
| CRP (ULN > 8.99 mg/dl) | 5/67 (7.5) | 14/232 (6.0) | 22/248 (8.9) | 10/167 (6.0) |
Values are n/N (%).
↵* Frequency of residual disease for patients who met DAPSA but not VLDA remission at Week 24. VLDA: very low disease activity; DAPSA: Disease Activity for Psoriatic Arthritis; cDAPSA: clinical DAPSA; HAQ: Health Assessment Questionnaire; PASI: Psoriasis Area and Severity Index; SJC: swollen joint count; TJC: tender joint count; CRP: C-reactive protein; ULN: upper limit of normal.